Recruiting

Breast Cancer PSMA PET

The purpose of this research is to determine the expression of Prostate Specific Membrane Antigen(PSMA) in metastatic Triple Negative Breast Cancer (TNBC) patients using Fludeoxyglucose F18 (FDG) PET/CT as the gold standard. The investigators hypothesize that most lesions in metastatic TNBC are PSMA-avid; and thus PSMA-based radionuclide therapy can be a valid treatment option for TNBC, and clinical trials can be designed for this purpose. Thirty metastatic TNBC patients will be enrolled and will be on the study…

ClinicalTrials.gov IDNCT06586047

PhaseEARLY_PHASE1

Enrollment30

SponsorAhmad Shariftabrizi

Age18 Years

SexFEMALE

I'm interested View official listing

Conditions studied

Triple Negative Breast Cancer

About this study

Interventions

Diagnostic Test: PET imaging — Imaging with FDG PET/CT and Pyl PET/CT in triple negative breast cancer

Primary outcomes

Lesion detection sensitivity analysis (4 weeks)

Eligibility information

Inclusion Criteria: * Female \>= 18 years of age * Patients in distantly metastatic TNBC based on the initial diagnosis biopsy. * Patient should have FDG positive metastatic lesions on the initial PET/CT scan performed in this study to be further included. Exclusion Criteria: * Patients with known active other malignancy. * Unable to tolerate PET/CT procedure. * Pregnant or breastfeeding. * Patients with any medical condition that might compromise the safety of subject during PET acquisitions.

Study locations

University of Iowa Healthcare, Iowa City, Iowa 52242 United States

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-28.